Clinical features of 66 lymphoma patients presenting with a fever of unknown origin

Internal Medicine

Volumn 51, Issue 18, 2012, Pages 2529-2536

  Zhang, Jing ^a   Chen, Bobin ^a   Xu, Xiaoping ^a   Lin, Zhiguang ^a   Huang, Bo ^a   Song, Jing ^a   Lin, Guowei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Etiology; Fever of unknown origin; Lymphoma; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; BETA LACTAM; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; LACTATE DEHYDROGENASE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; AGE DISTRIBUTION; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; LYMPH NODE BIOPSY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NIGHT SWEAT; PANCYTOPENIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PYREXIA IDIOPATHICA; REMISSION; RESTOSPECTIVE STUDY; WEIGHT REDUCTION;

ADULT; BETA 2-MICROGLOBULIN; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; HYPOALBUMINEMIA; L-LACTATE DEHYDROGENASE; LYMPHOMA; MALE; MIDDLE AGED; PANCYTOPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84867871951     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7817     Document Type: Article

References (46)

1. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on100 cases. Medicine 40: 1-30, 1961
2. Durack DT, Street AC. Fever of unknown origin-reexamined andredefined. Curr Clin Top Infect Dis 11: 35-51, 1991
3. Colpan A, Onguru P, Erbay A, et al. Fever of unknown origin analysis of 71 consecutive cases. Am J Med Sci 334: 92-96, 2007
4. Kucukardali Y, Oncul O, Cavuslu S, et al. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. Int J Infect Dis 12: 71-79, 2008
5. Cunha BA. Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. Infect Dis Clin North Am 21: 1137-1187, 2007
6. Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin-the challenge continues. Arch Intern Med 163: 1033-1041, 2003
7. Wei W, Hesheng L. Malignancy in Chinese adults presenting as fever of unknown origin. Int J Clin Pract 57: 508-512, 2003
8. Sterdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. In: Volume 2: IARC WHO classification of tumours, No 2. IARC Press, Lyon,France, 2008
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
10. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 92 (6 Suppl): 1684-1688, 2001
11. Mao JF, Liu ZY, Zhao YQ. The diagnosis of non-Hodgkin's lymphoma (NHL) with fever. Beijing Medical Journal 25: 372-374, 2003
12. Wang Z, Feng JP, Wang Ch, et al. Malignant lymphoma first presenting as fever of unknown origin: a clinical and pathological analysis of 48 cases. Chinese General Pracitce 12: 686-687, 2009
13. Gross SA, Zhu X, Bao L, et al. A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol 88: 165-173, 2008
14. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, et al. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 31: 29-37, 2004
15. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multicentre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 34: 694-703, 2007
16. Lockmans D, Knockaert D, Maes A, et al. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 32: 191-196, 2001
17. Buysschaert I, Vanderschueren S, Blockmans D, et al. Contribution of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur J Intern Med 15: 151-156, 2004
18. Kjaer A, Lebech AM, Eigtved A, et al. Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging 31:622-626, 2004
19. Lorenzen J, Buchert R, Bohuslavizki KH. Value of FDG PET in patients with fever of unknown origin. Nucl Med Commun 22:779-783, 2001
20. Meller J, Altenvoerde G, Munzel U, et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a doublehead coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med 27: 1617-1625, 2000
21. Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 86: 26-38, 2007
22. Sheng JF, Sheng ZK, Shen XM, et al. Diagnostic value offluorine-18 fluorodeoxyglucose positron emission tomography/ computed tomography in patients with fever of unknown origin. Eur J Intern Med 22: 112-116, 2011
23. Kubota K, Nakamoto Y, Tamaki N, et al. FDG-PET for the diagnosis of fever of unknown origin: a Japanese multi-center study. Ann Nucl Med 25: 355-364, 2011
24. Stumpe KD, Urbielli M, Steinert HC, et al. Whole body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25: 721-728, 1998
25. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232: 823-829, 2004
26. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2- fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104: 1066-1074, 2005
27. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography(PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12: 825-830, 2001
28. Alam K, Jain A, Maheshwari V, et al. Fine-needle aspiration cytology diagnosis of non-Hodgkins lymphoma in a resourcechallenged environment. Diagn Cytopathol 39: 461-467, 2011
29. Hiraoka N, Yokote T, Nakayama-lchiyama S, et al. High fever and shock induced by interferon-ã and interleukin-6 produced by adultT-cell leukaemia/lymphoma cells. Leuk Res 34: e290-e291, 2010
30. Li Z, Liu WP, Tang Y, et al. Splenic T-cell and NK-cell lymphomas: a clinicopathologic and immunophenotypic analysis of 9 cases. Zhonghua Xue Ye Xue Za Zhi 28: 217-222, 2007
31. Takahashi N, Chubachi A, Kume M, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 74: 209- 213, 2001
32. Takahashi N, Miura I, Chubachi A, et al. A clinicopathological study of 20 patients with T/natural killer(NK)-cell lymphomaassociated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 74: 303- 308, 2001.
33. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous Panniculitis like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood 111: 838-845, 2008
34. Han AR, Lee HR, Park BB, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol 86: 493-498, 2007
35. Miyahara M, Sano M, Shibata K, et al. B-cell lymphomaassociated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 79: 378-388, 2000
36. Sano T, Sakai H, Takimoto K, et al. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphomaassociated with hemophagocytic syndrome. Int J Clin Oncol 12: 59-62, 2007
37. Shimada K, Kinoshita T, Naoe T, et al. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10: 895-902, 2009
38. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994, 1993
39. Chihara D, Oki Y, Ine S, et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50: 1999-2004, 2009
40. Beltran B, Quinones P, Morales D, et al. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/ lymphoma. Leuk Res 35: 334-339, 2011
41. Lindh J, Lenner P, Osterman B, et al. Prognostic significance of serum lactic dehydrogenase levels and fraction of S-phase cells in non-Hodgkin lymphomas. Eur J Haematol 50: 258-263, 1993
42. Gordon LI, Andersen J, Colgan J, et al. Advanced diffuse non- Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer 75: 865-873, 1995
43. Lin R, Wang SS, Zhou SY, et al. Analysis of alkaline phosphatase staining results in 238 cases of malignant lymphoma. Di Yi Yun Yi Da Xue Xue Bao 23: 1097-1098, 2003
44. Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol 93: 502-508, 2011
45. Chan WKS, Au WY, Wong CYO, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med 35: 571- 575, 2010
46. Ngeow JYY, Quek RHH, Ng DCE, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Annals of Oncology 20: 1543-1547, 2009